← All trials
NCT02022696
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2013
- Primary completion
- Dec 16, 2013
- Completion date
- Dec 16, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 1
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- National Human Genome Research Institute (NHGRI)Lead sponsor
- National Human Genome Research Institute (NHGRI)Overall official - principal investigator
- National Cancer Institute (NCI)Collaborator
- Duke UniversityCollaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.